Fetal bovine serum (FBS) is the liquid fraction of clotted blood from fetal calves. It contains a large amount of nutritional and macromolecular components necessary for cell growth. FBS also contains a variety of small molecules such as amino acids, sugars, lipids, and hormones. It is commonly used for biotechnology research purposes, including cancer research, development of biopharmaceuticals, human and animal vaccines, and other research purposes.
Explore More Insights@ https://www.alliedmarketresearch.com/request-sample/5261
Increase in research and development activities related to cell culture in scientific fields such as biopharmaceuticals and biotechnology is a major factor contributing to the growth of the market. Additionally, increasing use of FBS in primary cell cultures for in-vitro testing and drug screening are key factors expected to drive market growth.
Covid-19 Impact Analysis:
- Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans.
- The overall impact of COVID-19 remains positive for fetal bovine serum market as biopharmaceutical innovators are at the forefront of in vitro research and development for the search of vaccine and antiviral.
By application, the biopharmaceuticals-segment accounted for
the maximum market revenue in 2020 and is expected to dominate the forecast
period. The introduction of new biopharmaceuticals to treat various diseases
worldwide has led to a significant increase in biotech R&D activities.
By end-user, the biotechnology and pharmaceutical industries
segment accounted for the maximum market revenue in 2020 and is expected to
dominate over the forecast period. This segment is expected to exhibit high
growth rate due to significant increase in R&D for biopharmaceutical drug
development and cancer research.
North America was the leading revenue contributor to the
global market in 2020 due to increase in healthcare investments by
manufacturers and increase in R&D spending for various biotechnology
research purposes. Asia-Pacific is expected to witness the highest growth
during the forecast period owing to the increase in biotech R&D and the
presence of major market players in the region.
Key Players:
·
Danaher (Cytiva),
·
Merck KGaA (Sigma Aldrich),
·
HiMedia Laboratories Pvt., Ltd,
·
Bio-Techne,
·
Sera Scandia (Biowest),
·
Sartorius (Biological Industries),
·
Rocky Mountain Biologicals,
·
PAN-Biotech
·
Thermo Fisher Scientific Inc.
0 Comments